Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults

OBJECTIVES: In Canada, incidences of herpes zoster (HZ) and postherpetic neuralgia (PHN) are increasing, posing a significant burden on the healthcare system. This study aimed to determine the public health impact and cost effectiveness of an adjuvanted recombinant zoster vaccine (RZV) compared to n...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Appl Health Econ Health Policy
Autors principals: McGirr, Ashleigh, Van Oorschot, Desiree, Widenmaier, Robyn, Stokes, Michael, Ganz, Michael L., Jung, Hyosung, Varghese, Lijoy, Curran, Desmond
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2019
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6748891/
https://ncbi.nlm.nih.gov/pubmed/31250218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40258-019-00491-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars